Pharmacogenetic or the promise of a personalized medicine: Variability in drug metabolism and transport;La pharmacogénétique ou la promesse d'une médecine personnalisée: Variations du métabolisme et du transport des médicaments

Annales de Biologie Clinique

Volumn 62, Issue 5, 2004, Pages 499-511

  Allorge, D ^a   Loriot, M A ^b  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

Drug; Genetic polymorphism; Metabolism; Pharmacogenetic

Indexed keywords

ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; CYTOCHROME P450 2D6; DRUG; GLYCOPROTEIN P; METHYLTRANSFERASE; PSYCHOTROPIC AGENT; THIOPURINE METHYLTRANSFERASE;

GENETIC POLYMORPHISM; GENOTYPE; HUMAN; METABOLISM; PHARMACOGENETICS; PHENOTYPE; PHYSIOLOGY; REVIEW;

ANTICOAGULANTS; ANTINEOPLASTIC AGENTS; CYTOCHROME P-450 CYP2D6; GENOTYPE; HUMANS; METHYLTRANSFERASES; P-GLYCOPROTEIN; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS; PHENOTYPE; POLYMORPHISM, GENETIC; PSYCHOTROPIC DRUGS;

EID: 4544292592     PISSN: 00033898     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. Lazarou J, Pomeranz B, Corey P. Incidence of adverse drug reactions in hospitalized patients ; a meta-analysis of prospective studies. J Am Med Assoc 1998 ; 279 : 1200-5.
2. Pouyanne P, Haramburu F, Imbs J, Bégaud B. Admissions to hospital caused by adverse drug reactions : cross sectional incidence study. Br Med J 2000 ; 320 : 1036.
3. Evans W, Relling M. Pharmacogenomics : translating functional genomics into rational therapeutics. Science 1999 ; 286 : 487-91.
4. Vogel F. Moderne probleme der humangenetik. Ergebnisse der Inneren Medizin 1959 ; 12 : 52-125.
5. Beutler E. Study of glucose-6-phosphate deshydrogenase : history and molecular biology. Am J Hematol 1993 ; 42 : 53-8.
6. Ingelman-Sundberg M, Oscarson M, McLellan R. Polymorphic human cytochrome P450 enzymes : an opportunity for individualized drug treatment. TiPS 1999 ; 20 : 342-9.
7. Daly A. Pharmacogenetics of the major polymorphic metabolising enzymes. Fundam Clin Pharmacol 2003 ; 17 : 27-41.
8. Oscarson M. Pharmacogenetics of drug metabolising enzymes : importance for personalised medecine. Clin Chem Lab Med 2003 ; 41 : 573-80.
9. Beaune P, Loriot M. Bases moléculaires de la susceptibilité aux xénobiotiques : aspects métaboliques. Médecine/ Sciences 2000 ; 16 : 1051-6.
10. Meyer U. Genotype or phenotype : the definition of a pharmacogenetic polymorphism. Pharmacogenetics 1991 ; 1 : 66-7.
11. Gaedigk A. Interethnic differences of drug-metabolizing enzymes. Int J Clin Pharmacol Ther 2000 ; 38 : 61-8.
12. Zanger U, Raimundo S, Eichelbaum M. Cytochrome P450 2D6 : overview and update on pharmacology, genetics, biochemistry. Naunyn-Schmiedeberg's Arch Pharmacol 2004 ; 369 : 23-37.
13. Daly A. Development of analytical technology in pharmacogenetic research. Naunyn-Schmiedeberg's Arch Pharmacol 2004 ; 369 : 133-40.
14. . Schaeffeler E, Schwab M, Eichelbaum M, Zanger U. CYP2D6 genotyping strategy based on gene copy number determination by TaqMan real-time PCR. Hum Mutat 2003 ; 22 : 476-85.
15. Broly F, Marez D, Sabbagh N, et al. An efficient strategy for detection of known and new mutations of the CYP2D6 gene using single strand conformation polymorphism analysis. Pharmacogenetics 1995 ; 5 : 373-84.
16. Shi M. Enabling large-scale pharmacogenetic studies by high-throughput mutation detection and genotyping technologies. Clin Chem 2001 ; 47 : 164-72.
17. Bertilsson L, Dahl M, Dalen P, Al-Shurbaji A. Molecular genetics of CYP2D6 : clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol 2002 ; 53 : 111-22.
18. Dalen P, Dahl M, Bertilsson L, Nordin J, Bertilsson L. 10-hydroxylation of nortryptiline in white persons with 0,1,2,3, and 13 functional CYP2D6 genes. Clin Pharmacol Ther 1998 ; 63 : 444-52.
19. Kawanishi C, Lundgren S, Agren H, Bertilsson L. Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders : ultrarapid metabolism of antidepressants as a cause of non response. A pilot study. Eur J Clin Pharmacol 2004 ; 59 : 803-7.
20. Kirchheiner J, Brosen K, Dahl M, et al. CYP2D6 and CYP2C19 genotype-based dose recommendations for anti-depressants : a first step towards subpopulation-specific dosages. Acta Psychiatr Scand 2001 ; 104 : 173-92.
21. Daly A, King B. Pharmacogenetics of oral anticoagulants. Pharmacogenetics 2003 ; 13 : 247-52.
22. Aithal G, Day C, Kesteven P, Daly A. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999 ; 353 : 717-9.
23. Higashi M, Veenstra D, Kondo L, et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 2002 ; 287 : 1690-8.
24. Tassies D, Freire C, Pijoan J, et al. Pharmacogenetics of acenocoumarol : cytochrome P450 CYP2C9 polymorphisms influence dose requirements and stability of anticoagulation. Haematologica 2002 ; 87 : 1185-91.
25. Rost S, Fregin A, Ivaskevicius V, et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 2004 ; 427 : 537-41.
26. Krynetski E, Evans W. Drug methylation in cancer therapy : lessons from the TPMT polymorphism. Oncogene 2003 ; 22 : 7403-13.
27. Schutz E, Gummert J, Mohr F, Oellerich M. Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient. Lancet 1993 ; 341 : 436.
28. Lennard L, Van Loon J, Lilleyman J, Weinshilboum R. Thiopurine pharmacogenetics in leukemia : correlation of erythrocyte thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations. Clin Pharmacol Ther 1987 ; 41 : 18-25.
29. Weinshilboum R, Sladek S. Mercaptopurine pharmacogenetics : monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980 ; 32 : 651-62.
30. McLeod H, Lin J, Scott E, Pui C, Evans W. Thiopurine methyltransferase activity in American white subjects and black subjects. Clin Pharmacol Ther 1994 ; 55 : 15-20.
31. Lennard L, Lilleyman J, Van Loon J, Weinshilboum R. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet 1990 ; 336 : 225-9.
32. Evans W, Hon Y, Bomgaars L, et al. Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. J Clin Oncol 2001 ; 19 : 2293-301.
33. Relling M, Hancock M, Rivera G, et al. Mercaptopurine therapy intolerance and heterozygoty at the thiopurine S-methyl-transferase gene locus. J Natl Cancer Inst 1999 ; 91 : 2001-8.
34. Dervieux T, Medard Y, Baudouin V, et al. Thiopurine methyltransferase activity and its relationship to the occurrence of rejection episodes in paediatric renal transplant recipients treated with azathioprine. Br J Clin Pharmacol 1999 ; 48 : 793-800.
35. Veenstra D, Higashi M, Phillips K. Assessing the cost-effectiveness of pharmacogenomics. AAPS Pharm Sci 2000 ; 23 : E29.
36. Ulrich C, Robien K, McLeod H. Cancer pharmacogenetics : polymorphisms, pathways and beyond. Nature Rev Cancer 2003 ; 3 : 912-20.
37. Pullarkat S, Stoehlmacher J, Ghaderi V, et al. Thymidilate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J 2001 ; 1 : 65-70.
38. Villafranca E, Okruzhnov Y, Dominguez M, et al. Polymorphisms of the repeated sequences in the enhancer region of the thymidilate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer. J Clin Oncol 2001 ; 19 : 1779-86.
39. Diaso R, Beavers T, Carpenter J. Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyridinemia and severe 5-fluorouracil-induced toxicity. J Clin Invest 1998 ; 81 : 47-51.
40. Raida M, Schwabe W, Hausler P, et al. Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase gene within the 5′-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls. Clin Cancer Res 2001 ; 7 : 2832-9.
41. Iyer L, King C, Whitington P, et al. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its metabolite (SN-38) in human liver microsomes. J Clin Invest 1998 ; 101 : 847-54.
42. Ando Y, Saka H, Ando M, et al. Polymorphisms of UDP-glucuronosyl- transferase gene and irinotecan toxicity : a pharmacogenetics analysis. Cancer Res 2000 ; 60 : 6921-6.
43. Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene : multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000 ; 97 : 3473-8.
44. Fellay J, Marzolini C, Meaden E, et al. Swiss HIV Cohort Study. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1 : a pharmacogenetics study. Lancet 2002 ; 359 : 30-6.
45. Macphee I, Fredericks S, Tai T, et al. Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement. Transplantation 2002 ; 74 : 1486-9.
46. Anglicheau D, Verstuyft C, Laurent-Puig P, et al. Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients. J Am Soc Nephrol 2003 ; 14 : 1889-96.
47. Farrell R, Murphy A, Long A, et al. High multidrug resistance (P-glycoprotein 170) expression in inflammatory bowel disease patients who fail medical therapy. Gastroenterology 2000 ; 118 : 279-88.